
|Articles|September 20, 2012
Yervoy footer
Advertisement
© 2012 Bristol-Myers Squibb Company, Princeton, NJ 08543 U.S.A.
731US12WA22001 10/12
Newsletter
Stay up to date on recent advances in the multidisciplinary approach to cancer.
Advertisement
Advertisement
Advertisement
Trending on CancerNetwork
1
Sacituzumab Govitecan Does Not Meet Statistical Significance in HR+/HER2– mBC
2
Frontline Giredestrant Displays IDFS Improvement vs SOC ET in ER+/HER2– BC
3
Pembrolizumab/Radiation Improves T Cell Infiltration in Early Breast Cancer
4
Resecting MRI-Detected Disease Doesn’t Improve Outcomes in Early-Stage BC
5

















































































